Mitsuru Moriyama

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Sustained molecular response after discontinuation of ropeginterferon alfa-2b in a young patient with polycythemia vera

Sustained molecular response after discontinuation of ropeginterferon alfa-2b in a young patient with polycythemia vera

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 29, 2026

Activity of Ponatinib and Vitamin K2 Against Myelodysplastic Syndrome and Acute Myeloid Leukemia Cells.

Activity of Ponatinib and Vitamin K2 Against Myelodysplastic Syndrome and Acute Myeloid Leukemia Cells.

Journal: Anticancer research

Published: December 24, 2025

Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells.

Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells.

Journal: Hematology reports

Published: October 22, 2025

Real-world pharmacokinetics of venetoclax in patients with acute myeloid leukemia in Japan.

Real-world pharmacokinetics of venetoclax in patients with acute myeloid leukemia in Japan.

Journal: Blood neoplasia

Published: August 12, 2025

Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells.

Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells.

Journal: Discover oncology

Published: February 28, 2025

Glutaminase 1 plays critical roles in myelodysplastic syndrome and acute myeloid leukemia cells.

Glutaminase 1 plays critical roles in myelodysplastic syndrome and acute myeloid leukemia cells.

Journal: Cancer biomarkers : section A of Disease markers

Published: August 30, 2024

Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects.

Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: March 16, 2024

Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.

Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.

Journal: Medical oncology (Northwood, London, England)

Published: March 03, 2024

Clonal identification and homology differentiate primary central nervous system lymphoma from non-central nervous system lymphoplasmacytic lymphoma: a case report.

Clonal identification and homology differentiate primary central nervous system lymphoma from non-central nervous system lymphoplasmacytic lymphoma: a case report.

Journal: Journal of medical case reports

Published: February 24, 2024

Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.

Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.

Journal: Leukemia & lymphoma

Published: February 01, 2024

Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.

Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.

Journal: World journal of oncology

Published: December 16, 2023

WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment.

WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment.

Journal: Cancer cell international

Published: December 18, 2022

Showing 1-12 of 27

Last Updated: 09/26/2026